OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that it has appointed Borys Shor, PhD to its Antibody Drug Conjugate (ADC) Advisory Board. In his role, Dr. Shor will assist the Company in the selection of antibody and payloads to be developed using the Company’s tunable ADC platform leveraging its proprietary pH-sensitive SiLinker™ silicone linker technology.
Dr. Shor has 20 years of experience in leading oncology discovery programs and external R&D partnerships at large pharma (Pfizer, Wyeth) and biotech companies, with specific focus on preclinical discovery and development of small molecule kinase inhibitors, biologics and nanoparticles. He is a founder and the CEO of Manhattan BioSolutions Inc. Dr. Shor also serves as a BioEntrepreneur-In-Residence with the Long Island Bioscience Hub and is a founder of BioIDEA, a biotech pitching forum in New York City. Previously at Pfizer, Boris led cross-functional oncology research teams to develop novel antibody-drug conjugates and supported Biological License Application (BLA) filing for Inotuzumab, which was approved for the treatment of leukemia in 2017. Prior to that, Dr. Shor served as a project team leader at the department of Oncology Discovery at Wyeth Pharmaceuticals, managing the discovery and characterization of novel kinase inhibitors for the treatment of cancer.
He currently serves on the executive management team of early-stage biotech companies and is a life sciences investment advisor for a biotech hedge fund. Dr. Shor earned MS degree in molecular genetics from the St. Petersburg State University. He also received a PhD in Molecular and Cell Biology at the SUNY Downstate Medical Center and performed a postdoctoral fellowship in the Inflammation Research team at Johnson & Johnson Pharmaceutical R&D prior to joining Wyeth.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240822112221/en/